Boulder, CO, United States of America

Guy Pa Vigers

USPTO Granted Patents = 1 

Average Co-Inventor Count = 27.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Guy Pa Vigers

Introduction: Guy Pa Vigers, a prominent inventor based in Boulder, CO, has made significant contributions to the field of cancer research through his innovative approaches. With a focus on developing inhibitors for KRas G12D, his work aims to provide new avenues for effective cancer treatments. His ingenuity is evidenced by the patent he holds, showcasing his commitment to advancing medical science.

Latest Patents: Guy Pa Vigers holds a valuable patent related to KRas G12D inhibitors. This patent outlines compounds specifically designed to inhibit the activity of the KRas G12D protein, which plays a crucial role in the development of certain cancers. The patented compounds, depicted by a general structure represented in Formula (I), are expected to pave the way for new pharmaceutical compositions aimed at treating cancer effectively.

Career Highlights: Throughout his career, Guy has worked with notable companies in the biotechnology industry, including Mirati Therapeutics, Inc. and Array Biopharma Inc. His tenure at these organizations allowed him to collaborate with some of the brightest minds in the field and contribute to cutting-edge research in cancer therapies.

Collaborations: Guy has been fortunate to work alongside talented individuals such as Xiaolun Wang and Aaron Craig Burns. These collaborations have enriched his research and have been instrumental in driving forward innovative solutions in cancer treatment.

Conclusion: Guy Pa Vigers exemplifies the spirit of innovation and dedication in cancer research. His patented work on KRas G12D inhibitors symbolizes the impact that determined inventors can have in the medical field. As technology and science continue to evolve, contributions from inventors like Vigers are vital for ushering in new treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…